Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes
Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Go...
Gespeichert in:
Veröffentlicht in: | Clinical genetics 2015-01, Vol.87 (1), p.11-20 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 20 |
---|---|
container_issue | 1 |
container_start_page | 11 |
container_title | Clinical genetics |
container_volume | 87 |
creator | Cook, J.R. Carta, L. Galatioto, J. Ramirez, F. |
description | Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions. |
doi_str_mv | 10.1111/cge.12436 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1647012153</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1647012153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0EokvhwB9AlrjAIa0dx44tTmjVLqDycVjE0Zo4k8UlcYKdAPvv8bJtD0hI-DKy9cwjzbwm5ClnZzyfc7fDM15WQt0jKy6MKRhj1X2yysUUhitxQh6ldJ2vopbmITkpK63q_L4i0xpi68cfkNzSQ6QDBN9hmmH2Y0jUB_oeYgeBpn1o4zgghdDSiD3M2NLWJ4SE6RUdln72U490hwETdbAkH3Y0-cEftNNXDOO8nzA9Jg866BM-uamn5PPlxXb9prj6uHm7fn1VOFkKVThkxhgFDLtS19hBU7KmQZSGgWpaLVoF2NWATa2rUqNEaFA00unKYd05cUpeHL1THL8veSI7-OSw7yHguCTLVVUzXnIp_gPNO9W8liyjz_9Cr8clhjzIgdKVUVroTL08Ui6OKUXs7BT9AHFvObOHxGxOzP5JLLPPboxLM2B7R95GlIHzI_DT97j_t8muNxe3yuLY4dOMv-46IH6zqs4_wH75sLHby3dMfpKV3Yrf73exFQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1638496838</pqid></control><display><type>article</type><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</creator><creatorcontrib>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</creatorcontrib><description>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</description><identifier>ISSN: 0009-9163</identifier><identifier>EISSN: 1399-0004</identifier><identifier>DOI: 10.1111/cge.12436</identifier><identifier>PMID: 24867163</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>angiotensin receptor blockers (ARBs) ; Animals ; Aortic Aneurysm, Thoracic - genetics ; Aortic Aneurysm, Thoracic - physiopathology ; Arachnodactyly - genetics ; Arachnodactyly - physiopathology ; calcium channel blockers ; cardiomyopathy ; Cardiovascular Abnormalities - genetics ; Cardiovascular Abnormalities - physiopathology ; Cardiovascular disease ; connective tissue ; Craniosynostoses - genetics ; Craniosynostoses - physiopathology ; Fibrillin-1 ; Fibrillins ; Gene therapy ; Ghent nosology ; Humans ; Loeys-Dietz Syndrome - genetics ; Loeys-Dietz Syndrome - physiopathology ; Marfan syndrome ; Marfan syndrome (MFS) ; Marfan Syndrome - genetics ; Marfan Syndrome - physiopathology ; Marfan Syndrome - therapy ; Mice ; Microfilament Proteins - genetics ; Mortality ; mutations in gene for fibrillin-1 (FBN1) ; Signal Transduction - genetics ; TGFβ ; thoracic and abdominal aortic aneurysm ; Transforming Growth Factor beta - antagonists & inhibitors ; Transforming Growth Factor beta - metabolism ; valvulopathy ; β-blockers</subject><ispartof>Clinical genetics, 2015-01, Vol.87 (1), p.11-20</ispartof><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</citedby><cites>FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fcge.12436$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fcge.12436$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24867163$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cook, J.R.</creatorcontrib><creatorcontrib>Carta, L.</creatorcontrib><creatorcontrib>Galatioto, J.</creatorcontrib><creatorcontrib>Ramirez, F.</creatorcontrib><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><title>Clinical genetics</title><addtitle>Clin Genet</addtitle><description>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</description><subject>angiotensin receptor blockers (ARBs)</subject><subject>Animals</subject><subject>Aortic Aneurysm, Thoracic - genetics</subject><subject>Aortic Aneurysm, Thoracic - physiopathology</subject><subject>Arachnodactyly - genetics</subject><subject>Arachnodactyly - physiopathology</subject><subject>calcium channel blockers</subject><subject>cardiomyopathy</subject><subject>Cardiovascular Abnormalities - genetics</subject><subject>Cardiovascular Abnormalities - physiopathology</subject><subject>Cardiovascular disease</subject><subject>connective tissue</subject><subject>Craniosynostoses - genetics</subject><subject>Craniosynostoses - physiopathology</subject><subject>Fibrillin-1</subject><subject>Fibrillins</subject><subject>Gene therapy</subject><subject>Ghent nosology</subject><subject>Humans</subject><subject>Loeys-Dietz Syndrome - genetics</subject><subject>Loeys-Dietz Syndrome - physiopathology</subject><subject>Marfan syndrome</subject><subject>Marfan syndrome (MFS)</subject><subject>Marfan Syndrome - genetics</subject><subject>Marfan Syndrome - physiopathology</subject><subject>Marfan Syndrome - therapy</subject><subject>Mice</subject><subject>Microfilament Proteins - genetics</subject><subject>Mortality</subject><subject>mutations in gene for fibrillin-1 (FBN1)</subject><subject>Signal Transduction - genetics</subject><subject>TGFβ</subject><subject>thoracic and abdominal aortic aneurysm</subject><subject>Transforming Growth Factor beta - antagonists & inhibitors</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>valvulopathy</subject><subject>β-blockers</subject><issn>0009-9163</issn><issn>1399-0004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhi0EokvhwB9AlrjAIa0dx44tTmjVLqDycVjE0Zo4k8UlcYKdAPvv8bJtD0hI-DKy9cwjzbwm5ClnZzyfc7fDM15WQt0jKy6MKRhj1X2yysUUhitxQh6ldJ2vopbmITkpK63q_L4i0xpi68cfkNzSQ6QDBN9hmmH2Y0jUB_oeYgeBpn1o4zgghdDSiD3M2NLWJ4SE6RUdln72U490hwETdbAkH3Y0-cEftNNXDOO8nzA9Jg866BM-uamn5PPlxXb9prj6uHm7fn1VOFkKVThkxhgFDLtS19hBU7KmQZSGgWpaLVoF2NWATa2rUqNEaFA00unKYd05cUpeHL1THL8veSI7-OSw7yHguCTLVVUzXnIp_gPNO9W8liyjz_9Cr8clhjzIgdKVUVroTL08Ui6OKUXs7BT9AHFvObOHxGxOzP5JLLPPboxLM2B7R95GlIHzI_DT97j_t8muNxe3yuLY4dOMv-46IH6zqs4_wH75sLHby3dMfpKV3Yrf73exFQ</recordid><startdate>201501</startdate><enddate>201501</enddate><creator>Cook, J.R.</creator><creator>Carta, L.</creator><creator>Galatioto, J.</creator><creator>Ramirez, F.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201501</creationdate><title>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</title><author>Cook, J.R. ; Carta, L. ; Galatioto, J. ; Ramirez, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5236-ce09996a0ef287efab20bbee590a6bd83d6aef7aeb78428e5eabe3b5c84ce7fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>angiotensin receptor blockers (ARBs)</topic><topic>Animals</topic><topic>Aortic Aneurysm, Thoracic - genetics</topic><topic>Aortic Aneurysm, Thoracic - physiopathology</topic><topic>Arachnodactyly - genetics</topic><topic>Arachnodactyly - physiopathology</topic><topic>calcium channel blockers</topic><topic>cardiomyopathy</topic><topic>Cardiovascular Abnormalities - genetics</topic><topic>Cardiovascular Abnormalities - physiopathology</topic><topic>Cardiovascular disease</topic><topic>connective tissue</topic><topic>Craniosynostoses - genetics</topic><topic>Craniosynostoses - physiopathology</topic><topic>Fibrillin-1</topic><topic>Fibrillins</topic><topic>Gene therapy</topic><topic>Ghent nosology</topic><topic>Humans</topic><topic>Loeys-Dietz Syndrome - genetics</topic><topic>Loeys-Dietz Syndrome - physiopathology</topic><topic>Marfan syndrome</topic><topic>Marfan syndrome (MFS)</topic><topic>Marfan Syndrome - genetics</topic><topic>Marfan Syndrome - physiopathology</topic><topic>Marfan Syndrome - therapy</topic><topic>Mice</topic><topic>Microfilament Proteins - genetics</topic><topic>Mortality</topic><topic>mutations in gene for fibrillin-1 (FBN1)</topic><topic>Signal Transduction - genetics</topic><topic>TGFβ</topic><topic>thoracic and abdominal aortic aneurysm</topic><topic>Transforming Growth Factor beta - antagonists & inhibitors</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>valvulopathy</topic><topic>β-blockers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cook, J.R.</creatorcontrib><creatorcontrib>Carta, L.</creatorcontrib><creatorcontrib>Galatioto, J.</creatorcontrib><creatorcontrib>Ramirez, F.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cook, J.R.</au><au>Carta, L.</au><au>Galatioto, J.</au><au>Ramirez, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes</atitle><jtitle>Clinical genetics</jtitle><addtitle>Clin Genet</addtitle><date>2015-01</date><risdate>2015</risdate><volume>87</volume><issue>1</issue><spage>11</spage><epage>20</epage><pages>11-20</pages><issn>0009-9163</issn><eissn>1399-0004</eissn><abstract>Cardiovascular abnormalities are the major cause of morbidity and mortality in Marfan syndrome (MFS) and a few clinically related diseases that share, with MFS, the pathogenic contribution of dysregulated transforming growth factor β (TGFβ) signaling. They include Loeys–Dietz syndrome, Shprintzen–Goldberg syndrome, aneurysm–osteoarthritis syndrome and syndromic thoracic aortic aneurysms. Unlike the causal association of MFS with mutations in an extracellular matrix protein (ECM), the aforementioned conditions are due to defects in components of the TGFβ pathway. While TGFβ antagonism is being considered as a potential new therapy for these heritable syndromes, several points still need to be clarified in relevant animal models before this strategy could be safely applied to patients. Among others, unresolved issues include whether elevated TGFβ signaling is responsible for all MFS manifestations and is the common trigger of disease in MFS and related conditions. The scope of our review is to highlight the clinical and experimental findings that have forged our understanding of the natural history and molecular pathogenesis of cardiovascular manifestations in this group of syndromic conditions.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>24867163</pmid><doi>10.1111/cge.12436</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-9163 |
ispartof | Clinical genetics, 2015-01, Vol.87 (1), p.11-20 |
issn | 0009-9163 1399-0004 |
language | eng |
recordid | cdi_proquest_miscellaneous_1647012153 |
source | MEDLINE; Access via Wiley Online Library |
subjects | angiotensin receptor blockers (ARBs) Animals Aortic Aneurysm, Thoracic - genetics Aortic Aneurysm, Thoracic - physiopathology Arachnodactyly - genetics Arachnodactyly - physiopathology calcium channel blockers cardiomyopathy Cardiovascular Abnormalities - genetics Cardiovascular Abnormalities - physiopathology Cardiovascular disease connective tissue Craniosynostoses - genetics Craniosynostoses - physiopathology Fibrillin-1 Fibrillins Gene therapy Ghent nosology Humans Loeys-Dietz Syndrome - genetics Loeys-Dietz Syndrome - physiopathology Marfan syndrome Marfan syndrome (MFS) Marfan Syndrome - genetics Marfan Syndrome - physiopathology Marfan Syndrome - therapy Mice Microfilament Proteins - genetics Mortality mutations in gene for fibrillin-1 (FBN1) Signal Transduction - genetics TGFβ thoracic and abdominal aortic aneurysm Transforming Growth Factor beta - antagonists & inhibitors Transforming Growth Factor beta - metabolism valvulopathy β-blockers |
title | Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T16%3A45%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20manifestations%20in%20Marfan%20syndrome%20and%20related%20diseases;%20multiple%20genes%20causing%20similar%20phenotypes&rft.jtitle=Clinical%20genetics&rft.au=Cook,%20J.R.&rft.date=2015-01&rft.volume=87&rft.issue=1&rft.spage=11&rft.epage=20&rft.pages=11-20&rft.issn=0009-9163&rft.eissn=1399-0004&rft_id=info:doi/10.1111/cge.12436&rft_dat=%3Cproquest_cross%3E1647012153%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1638496838&rft_id=info:pmid/24867163&rfr_iscdi=true |